The ratings of 8 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Concordia Healthcare Corp.’s (CXRX) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in operating margin growth and earnings growth. For more information, get Portfolio Grader’s complete analysis of CXRX stock.

Horizon Pharma plc (HZNP) is having a tough week. The company’s rating falls from a C to a D. Horizon Pharma plc is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of HZNP stock.

Paratek Pharmaceuticals Inc (PRTK) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PRTK stock.

Intersect ENT Inc (XENT) slips from a D to a F this week. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of XENT stock.

Slipping from a D to a F rating, Aralez Pharmaceuticals Inc. (ARLZ) takes a hit this week. The company also gets F’s in operating margin growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARLZ stock.

This week, AcelRx Pharmaceuticals, Inc. (ACRX) drops from a C to a D rating. AcelRx Pharmaceuticals, Inc. focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ACRX stock.

Alimera Sciences, Inc. (ALIM) declines this week from a D to a F. Alimera Sciences, Inc. engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company also gets F’s in earnings revisions and free cash flow. For more information, get Portfolio Grader’s complete analysis of ALIM stock.

Marinus Pharmaceuticals Inc (MRNS) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MRNS stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.